iiinova — where your digital self keeps evolving

Reposted by Adam Sowalsky

Journal of Clinical Investigation @jci.org · 28/11/2025

In prostate cancer, the initial biopsy carries more information than we thought @adam-sowalsky.bsky.social & team discover aggressive untreated prostate cancers harbor a tumor cell subpopulation with elevated HER2 levels that may be sensitive to inhibitors: www.jci.org/articles/vie...

062

Adam Sowalsky @adam-sowalsky.bsky.social · 04/09/2025

I'm pleased to share the latest paper from my lab, published online today at @jclinical-invest.bsky.social www.jci.org/articles/vie.... Patients with high risk prostate cancers that resist intense androgen derivation therapy harbor cancer cells that are sensitive to HER2 inhibitors. A "skytorial."

jci.org

JCI - Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibition

143

Reposted by Adam Sowalsky

Freddy E Escorcia, MD/PhD @freddyeescorcia.bsky.social · 21/05/2025

🚨New publication alert🚨 Typeset version of our most recent publication in European Urology just hit! Wonderful collaboration with @mishabeltran.bsky.social @adam-sowalsky.bsky.social and Pete Nelson at @fredhutch.bsky.social! 👇

162

Adam Sowalsky @adam-sowalsky.bsky.social · 08/05/2025

When I was on paternity leave with my son (who is now 6-1/2) my good friend and long-time collaborator Huihui Ye called and asked me to help with genomic profiling of a rare variant of kidney cancer. That paper was published today in @modernpathology.bsky.social. authors.elsevier.com/c/1l3Ih3B8d9...

170

Reposted by Adam Sowalsky

Freddy E Escorcia, MD/PhD @freddyeescorcia.bsky.social · 07/05/2025

Great mid-week news on the publication front! Could it be that our GPC3-selective radiotheranostics agents aimed at #HCC could be repurposed for neuroendocrine prostate cancer? Fun collaboration with Dr. Adam Sowalsky, Himisha Beltran and Peter Nelson! Stay tuned! #radiopharmaceuticals #pcsm

081

Reposted by Adam Sowalsky

Joshua Russo @jrpcfer.bsky.social · 19/01/2025

Happy to finally have this work out. Enza-resistance in PCa via upregulation of ARv7 and increased chromatin accessibility. Congrats to lead author (and newly minted PCF YI) Larysa Poluben! She put a tremendous amount of work into this and deserves all the 👏👏👏. pubmed.ncbi.nlm.nih.gov/39709604/

pubmed.ncbi.nlm.nih.gov

Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer - PubMed

Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in castration-resistant prostate cancer, but the extent to which they drive AR activity is unclear. We generated...

241